| Literature DB >> 28663807 |
Rui Soares1,2, Graça Rocha1,3, Célia Nogueira1, António Meliço-Silvestre1,4, Teresa Gonçalves1,2.
Abstract
INTRODUCTION: Viral protein R (Vpr) of human immunodeficiency virus type 1 (HIV-1) has been described as being involved in the progression of AIDS, and specific mutations are associated with long-term non-progressor patients. CASEEntities:
Keywords: AIDS/HIV-1; HAART; Vpr mutation; asymptomatic; long-term non-progressor
Year: 2014 PMID: 28663807 PMCID: PMC5415930 DOI: 10.1099/jmmcr.0.002709
Source DB: PubMed Journal: JMM Case Rep ISSN: 2053-3721
Clinical and laboratory data
| Characteristic/treatment | Day 1 | June 2010 | July 2010 | December 2010 | October 2011 | April 2012 |
| Age | 5 years, 1 month | 5 years, 3 month | 5 years, 4 months | 5 years, 9 months | 6 years, 7 months | 7 years, 1 month |
| Weight (kg) | 16 | 16.6 | 17.8 | 18.8 | 20.2 | 22 |
| Percentile | 25/50 | 25/50 | 25/50 | 25/50 | 25/50 | 25 |
| HIV RNA copies ml−1 | 1 073 899 | 680 | 123 | <20 | <20 | <20 |
| CD4+ T-cells ml−1 | 0 | 0.07 | 0.1 | 672 | 1310 | 1553 |
| CD4+ T-cells (%) | <1 | 2.1 | 2.9 | 17.8 | 34.7 | 41.1 |
| CD4+/CD8+ ratio | – | – | – | 0.3 | 0.63 | 0.75 |
| Months | 0 | 2 | 3 | 8 | 18 | 24 |
| Zidovudine | 130 | 130 | 150 | 150 | 150 | 150 |
| Lamivudine | 70 | 70 | 75 | 75 | 75 | 75 |
| Lopinavir/ritonavir | 160/20 | 160/20 | 200/25 | 200/25 | 200/25 | 200/25 |
* Day 1 was 6 days after admission.